A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib

INTRODUCTION: The central nervous system (CNS) is a common site of progression among patients with ROS1-rearranged lung cancer receiving crizotinib. We conducted a phase 2 study to evaluate the intracranial efficacy of lorlatinib in patients with ROS1-rearranged lung cancer who developed CNS-only pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Jaime L., Muzikansky, Alona, Lin, Jessica J., Krueger, Elizabeth A., Lennes, Inga T., Jacobson, Joseph O., Cheng, Michael, Heist, Rebecca S., Piotrowska, Zofia, Gainor, Justin F., Shaw, Alice T., Dagogo-Jack, Ibiay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257415/
https://www.ncbi.nlm.nih.gov/pubmed/35815322
http://dx.doi.org/10.1016/j.jtocrr.2022.100347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257415/
https://www.ncbi.nlm.nih.gov/pubmed/35815322
http://dx.doi.org/10.1016/j.jtocrr.2022.100347

Ejemplares similares